Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rhythm Pharmaceuticals ( (RYTM) ) has shared an update.
On July 9, 2025, Rhythm Pharmaceuticals entered into an underwriting agreement with Morgan Stanley & Co. LLC and BofA Securities, Inc. for the sale of 2,058,824 shares of its common stock at $85.00 per share, with an option for underwriters to purchase an additional 308,823 shares. The offering is expected to close on July 11, 2025, generating approximately $188.7 million in net proceeds, which the company plans to use for clinical development, commercialization activities for IMCIVREE, and general corporate purposes. This financial move is anticipated to support the company’s operations for at least the next 24 months.
The most recent analyst rating on (RYTM) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
Rhythm Pharmaceuticals’ stock score is bolstered by strong technical momentum and positive corporate events, such as successful trial results. However, financial performance issues due to ongoing unprofitability and negative valuation metrics weigh significantly on the overall score.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare genetic disorders of obesity. Its primary product is IMCIVREE, which targets specific genetic deficiencies.
Average Trading Volume: 734,114
Technical Sentiment Signal: Buy
Current Market Cap: $5.66B
Find detailed analytics on RYTM stock on TipRanks’ Stock Analysis page.